KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Amortization - Intangibles (2019 - 2026)

Pacira BioSciences has reported Amortization - Intangibles over the past 8 years, most recently at $14.3 million for Q1 2026.

  • For Q1 2026, Amortization - Intangibles changed 0.15% year-over-year to $14.3 million; the TTM value through Mar 2026 reached $57.3 million, changed 0.04%, while the annual FY2025 figure was $57.3 million, 0.02% changed from the prior year.
  • Amortization - Intangibles for Q1 2026 was $14.3 million at Pacira BioSciences, roughly flat from $14.3 million in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $14.3 million in Q1 2022 and troughed at $14.3 million in Q4 2022.
  • A 5-year average of $14.3 million and a median of $14.3 million in 2022 define the central range for Amortization - Intangibles.
  • Biggest five-year swings in Amortization - Intangibles: soared 628.11% in 2022 and later dropped 0.15% in 2023.
  • Year by year, Amortization - Intangibles stood at $14.3 million in 2022, then rose by 0.24% to $14.3 million in 2023, then changed by 0.0% to $14.3 million in 2024, then dropped by 0.15% to $14.3 million in 2025, then rose by 0.15% to $14.3 million in 2026.
  • Business Quant data shows Amortization - Intangibles for PCRX at $14.3 million in Q1 2026, $14.3 million in Q4 2025, and $14.3 million in Q3 2025.